{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["22(4)"],"submitter":["Levy R"],"funding":["European Research Council","Israel Science Foundation","MRA"],"pubmed_abstract":["Posttranslational spliced peptides (PTSPs) are a unique class of peptides that have been found to be presented by HLA class-I molecules in cancer. Thus far, no consensus has been reached on the proportion of PTSPs in the immunopeptidome, with estimates ranging from 2% to as high as 45% and stirring significant debate. Furthermore, the role of the HLA class-II pathway in PTSP presentation has been studied only in diabetes. Here, we exploit our large-scale cancer peptidomics database and our newly devised pipeline for filtering spliced peptide predictions to identify recurring spliced peptides, both for HLA class-I and class-II complexes. Our results indicate that HLA class-I-spliced peptides account for a low percentage of the immunopeptidome (less than 3.1%) yet are larger in number relati"],"journal":["Molecular & cellular proteomics : MCP"],"pagination":["100519"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10119686"],"repository":["biostudies-literature"],"pubmed_title":["Large-Scale Immunopeptidome Analysis Reveals Recurrent Posttranslational Splicing of Cancer- and Immune-Associated Genes."],"pmcid":["PMC10119686"],"pubmed_authors":["Shmueli MD","Bartok O","Ternette N","Alon M","Gumpert N","Cohen Shvefel S","Alter Regev T","Merbl Y","Dayan-Rubinov M","Levin Y","Levy R","Paes W","Samuels Y"],"additional_accession":[]},"is_claimable":false,"name":"Large-Scale Immunopeptidome Analysis Reveals Recurrent Posttranslational Splicing of Cancer- and Immune-Associated Genes.","description":"Posttranslational spliced peptides (PTSPs) are a unique class of peptides that have been found to be presented by HLA class-I molecules in cancer. Thus far, no consensus has been reached on the proportion of PTSPs in the immunopeptidome, with estimates ranging from 2% to as high as 45% and stirring significant debate. Furthermore, the role of the HLA class-II pathway in PTSP presentation has been studied only in diabetes. Here, we exploit our large-scale cancer peptidomics database and our newly devised pipeline for filtering spliced peptide predictions to identify recurring spliced peptides, both for HLA class-I and class-II complexes. Our results indicate that HLA class-I-spliced peptides account for a low percentage of the immunopeptidome (less than 3.1%) yet are larger in number relati","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Apr","modification":"2026-05-28T16:50:54.447Z","creation":"2025-02-19T04:16:03.422Z"},"accession":"S-EPMC10119686","cross_references":{"pubmed":["36828127"],"doi":["10.1016/j.mcpro.2023.100519"]}}